

Index

- ablation, percutaneous 501, 512–13, 514–15
 ACCP (American College of Chest Physicians) guidelines 139
 acetate, [⁶⁸C] 28, 246
 acquisition modes 7–8
 addition techniques 10
 adenocarcinoma 128, 129
 Barrett's esophagus 185–6
 breast 279–81
 colorectal 209, 211, 212, 214, 215–17
 endometrial 312–14
 esophageal 174, 182–4, 189–90, 490
 lung 161–4, 165–7
 malignancy of unknown origin 446
 pancreas 242, 250–2, 254, 255
 stomach 233, 240
 adenocarcinoma *in situ*, lung 128–30, 151–2, 153–4
 adenomas 19
 adipose tissue, FDG uptake 57, 58, 69–70, 71
 adrenal glands, FDG uptake 57, 58, 66
 AIDS related lymphomas 330, 347–9
 AJCC Cancer Staging Manual 293. *See also* tumor-nodal-metastasis classification
 algorithms, iterative reconstruction 10
 alpha blending 51
 American College of Chest Physicians. *See* ACCP
 American Joint Committee on Cancer. *See* AJCC
 amino acid radiotracers 20–1, 79
 anaplastic oligodendroglioma 97
 androgen receptor, PET probes 26–7
 anemia 236–8, 240
 angiogenesis, PET probes 24
 angular deviation 5
 Ann Arbor lymphoma staging system 331, 346
 annihilation photons 2
 apoptosis
 necrosis 22
 PET probes 21–2
 appendicitis 236–8
 aromatase inhibitors 268–9
 artifacts 15–18
 astrocytoma, cerebellar 438–9
 atomic number (Z) 1
 ATSM (diacetyl-bis-(N4-methylthiosemicarbazone) 25
 attenuation compensation 11–15
 atypical carcinoids 130
 BAC. *See* bronchioloalveolar carcinoma
 barium imaging 175
 Barrett's esophagus 174, 185–6
 Bartholin's cyst 295–301, 304
 BAT. *See* brown adipose tissue
 beta decay 2
 bi-linear transformation 14, 15
 biopsy planning 501
 brain tumors 79–80
 gastrointestinal stromal tumor 503, 505
 liver metastasis 506–7, 508–9, 510
 sarcomas 468
 bisphosphonates 407, 417
 birth, FDG uptake 295–301
 blood, FDG uptake 57, 58, 64
 bone scintigraphy 133, 406
 bone tissue, FDG uptake 57, 58, 67, 68, 334
 bone tumors/metastases 406–7
 breast cancer metastasis 415–17
 Ewing's sarcoma 420–1
 lung cancer metastasis 159–60, 409, 410
 myeloma metastases 418–19
 neuroendocrine tumor metastasis 422–3
 osteosarcoma 474
 pediatric case studies 430–1
 PET probes 25
 prostate cancer metastasis 425–6
 thyroid carcinoma metastasis 413–14
 brain, FDG uptake 55, 56, 57, 58, 60, 62
 brain tumors/metastases 75, 87
 amino acid radiotracers 79
 biopsy planning 79–80
 breast cancer metastasis 84–6
 FDG-PET 78–80, 82–3, 85
 gliomas 75–6, 97, 98, 99–100
 GBM 95–6
 glioblastoma 101–2
 lymphoma metastasis 82–3
 melanoma metastasis 87, 88, 89
 meningioma 91, 92–3
 metastases 76, 77, 84–6
 MRI 76–7
 pediatric case studies 438–9
 radiation injury 76
 SPECT 77–8, 85
 breast, FDG uptake 55, 57, 58, 62, 64
 breast cancer 267
 diagnosis 269, 270
 ductal adenocarcinoma 279–81
 ductal carcinoma 274, 275, 277–8, 285–7, 288–9
 FDG-PET, role 269–71
 incidental breast cancer 291–2
 malignancy of unknown origin 455–6
 PET probes 25–6
 positron emission mammography 271
 response to therapy 271, 279–81, 285–7, 488–9
 restaging/disease progression 282–4
 staging 267, 268, 269–71, 277–8
 treatment 267–9
 breast cancer metastasis 84–6
 biopsy planning 506–7
 bone 415–17
 brain 84–6
 malignancy of unknown origin 452–3
 bright scintillators 7
 bronchioloalveolar carcinoma 128–30, 151–2, 153–4
 bronchoscopy 133–4
 brown adipose tissue, FDG uptake 57, 58, 69–70, 71
 C-acetate 28, 246
 cancer with unknown primary. *See* malignancy of unknown origin
 carbon-11 electron capture 2
 carcinoembryonic antigen (CEA) 202, 446
 carcinoids 130, 131, 132
 carcinosarcoma, uterine 315–16
 caudal type homeobox transcription factor-2 (CDX2) 446
 cecal cancer 212, 214, 215–17, 229, 236–8. *See also* colorectal cancer
 cell death. *See* apoptosis
 cell proliferation
 amino acid radiotracers 79
 PET probes 21–2
 cervical cancer 306–9
 Chamberlain procedure 134
 chemotherapy, FDG uptake 56, 68, 70–2
 chest radiography 133
 cholangiocarcinoma 246–7, 256, 262–3
 choline-PET/CT 22–3, 426
 chondrosarcomas 466. *See also* sarcomas
 chronic lymphocytic leukemia (CLL) 351–3
 cirrhosis, liver 245
 cisplatin 446
 classical Hodgkin's lymphoma (cHL) 329–30, 331–2, 344–6, 358–60, 362–4. *See also* lymphoma

- classification. *See* staging;
 tumor-nodal-metastasis
 classification
- clinical drug trials 493–4
- C-methionine amino acid
 radiotracers 20, 79
- coincidence events, types 8–10, 11
- coincidence timing windows 7
- colorectal cancer 201, 203, 205.
See also gastrointestinal
 malignancies
- adenocarcinoma 209, 211,
 212, 214, 215–17
- biopsy planning 510
- cecal cancer with metastases
 229, 236–8
- clinical indications 204
- FDG-PET/PET/CT 202–3
- historical perspective 201–3
- metastases, percutaneous
 tumor ablation 512–13
- patient preparation/protocol
 203–4
- PET meta-analysis 202
- rectal cancer 216–20, 219–24,
 226–31
- response to therapy, monitoring
 203, 204–5, 215–17
- sigmoid colon cancer 226, 232–4
- squamous cell carcinoma,
 rectal 222, 226–31
- color look-up tables 37–8
- colors, component 35, 36–7
- Compton-scattered photons 9
- computerised information
 storage systems 35–6.
See also information
 systems
- contrast, image 38–40
- coronal viewing modes 46
 CRC. *See* colorectal cancer
- cryoablation, liver metastases
 514–15
- CT (computerised tomography)
 scanning
- colorectal cancer 202
- comparisons with PET/CT
 387–90, 387–90, 508–9
- esophageal cancer 175–6
- lung cancer 133
- malignant pleural
 mesothelioma 142
- pancreatic cancer 243
- response to therapy case
 studies 497–8
- sarcomas 467
- CT numbers 14
- CUP (cancer with unknown
 primary). *See* malignancy of
 unknown origin
- cytokeratins 445
- data modules 41, 42, 43, 44
- data processing information
 systems 40
- data transfer information
 systems 41
- data-addition 10
- databases 41
- data-subtraction 9–10
- DCIS (ductal carcinoma in situ)
 267, 268, 274, 275, 277–8,
 285–7, 288–9. *See also*
 breast cancer
- decay 1
- delayed-window randoms
 subtraction 9
- depth of interaction (DOI) 5–6
- detectors, PET 6–7, 8
- blocks 6
- size 4
- D-glucose 19
- diagnosis, PET/CT-guided 501.
See also biopsy planning
- DICOM (Digital Imaging and
 Communications in
 Medicine) 41–3, 44, 47–8
- diet, patient 19
- diethylstilbestrol (DES) 313
- diffuse large B-cell lymphomas
 (DLBCL) 329–32. *See also*
 lymphoma
- AIDS patient 347–9
- other case studies 351–3, 355–7
- semi-quantitative evaluation
 338
- DNA synthesis, PET probes 21–2
- DOI (depth of interaction) 5–6
- drug trials 493–4
- ductal carcinoma in situ.
See DCIS
- Early Lung Cancer Action
 Project (ELCAP) 136
- electron capture 2
- element numbers, databases 42
- endometrial adenocarcinoma
 312–14
- endoscopic ultrasound 176
- endoscopic retrograde
 cholangiopancreatography
 (ERCP) 243
- energy spectra 2
- EORTC (European Organization
 for Research and Treatment
 of Cancer) 205
- epithelial carcinomas, ovarian 321
- equations
 attenuation correction 13
- electron capture 2
- image fusion 51
- noise-equivalent count-rate 10
- positron decay 2
- random-coincidence
 count-rate 9
- system resolution 5
- esophageal cancer 174
- adenocarcinoma 182–4, 185–6
- adenocarcinoma with
 metastases 189–90
- Barrett's esophagus 185–6
- carcinoma with locoregional
 metastasis 187–8
- imaging other than PET/PET/
 CT 175–6
- metastatic 191–2, 196–7
- PET imaging 176–7
- post esophagectomy 194–5
- recurrence, detecting 178–9
- response to therapy 179, 198–9,
 490, 492
- staging/treatment 174–5, 177–8
- esophageal endoscopic
 ultrasound 134
- estrogen 268–9, 313, 321, 446
- estrogen receptor, PET probes
 25–6
- European Organization for
 Research and Treatment of
 Cancer (EORTC) guidelines
 205
- Ewing's sarcoma 406, 420–1,
 482–4. *See also* sarcomas
- pediatric case studies 432–3
- FABC (^{18}F)-1-amino-3-
 fluorocyclobutane) 21
- false positive PET/CT results.
See physiological uptake
- fan-beam projection data 3
- fast scintillators 7
- fat, brown, FDG uptake 57, 58,
 69–70, 71
- fatty acid synthesis, PET probes
 27–8
- FAZA (F-labeled fluoroazomycin
 arabinoside) 25
- FCH/FECH (fluoroethyl
 analogs) 23
- FDG (fluorodeoxyglucose)
 19–20, 25. *See also* glucose;
 physiological FDG uptake
- FDG-PET/CT
- bone tumors/metastases 406–7
- brain tumors 78–80, 82–3, 85
- breast cancer 269–71
- cholangiocarcinoma 246–7
- colorectal cancer 202–3
- esophageal cancer 176–7, 179
- gallbladder carcinoma 247, 261
- head and neck cancer 103,
 116–18
- hepatocellular carcinoma 245–6
- lung cancer 133, 135, 136–40,
 141–2
- lymphoma 331–4
- malignant pleural
 mesothelioma 142–3
- melanoma 366, 392–4
- pancreatic cancer 244
- sarcomas 467–70, 474–5
- FDHT (fluorodihydrotestosterone)
 26–7
- FDOPA (6- ^{18}F)-fluoro-L-dopa)
 20–1
- FECH (fluoroethyl analogs) 23
- female reproductive tract 293.
See also ovarian cancer;
 uterus
- cervical cancer 306–9
- endometrial adenocarcinoma
 312–14
- physiological FDG uptake 294,
 295–301
- response to therapy,
 monitoring 323
- staging 293–4, 323
- technical issues 294
- vulvar cancer 303–5, 306
- FES (fluoro-17beta-estradiol)
 PET probes 26
- FET (0-(2- ^{18}F)-fluoroethyl)-L-
 tyrosine) 21
- FETA (fluoroetanidazole) 25
- FETNIM (fluoroerythroni
 troimidazole) 25
- fibroids 19, 295–301
- fibromas 321
- filtered backprojection 10
- FLT (F-labeled thymidine) 22, 470
- fluoride 25
- fluoroacetate (FAc) 28
- fluorine-18 fluorodeoxyglucose.
See FDG-PET
- fluorine-18 fluoromisonidazole
 (FMISO) 24–5, 470
- fluorine-18 labeled thymidine
 (FLT) 22, 470
- sarcomas 470
- FMAU (fluoropyrimidine) 22
- FMDHT (fluoromethylidi
 hydrotestosterone) 27
- FMISO (fluoromisonidazole)
 24–5, 470
- FNCLCC (Federation Nationale
 des Centre de Lutte Contre
 le Cancer) 466
- full-width-at-half-maximum
 (FWHM) 4
- fused imaging 48, 50–1
- Ga-labeled octreotide analogs 27
- gadolinium 243
- Galacto-RGD 24
- gallbladder carcinoma 247, 255,
 260–1
- gamma radiation 2
- gastric pull-up 194–5, 196–7
- gastroesophageal reflux disease
 174, 185–6
- gastrointestinal cancer 201,
 460–1. *See also* colorectal
 cancer; GIST; stomach
 cancer
- gastrointestinal tract, FDG
 uptake 57, 58, 65–6
- GBM (glioblastoma multiforme)
 95–6, 101–2
- genital tract, female. *See* female
 reproductive tract

Index

- geometry, PET detectors 7–8
 GERD (gastroesophageal reflux disease) 174, 185–6
 germ cell tumors 321–2. *See also* ovarian cancer
 GIST (gastro-intestinal stromal tumor) 206, 237, 237–41, 476–7, 478. *See also* sarcomas biopsy planning 503, 505
 glioblastoma multiforme 95–6, 101–2
 gliomas 75–6, 97, 98, 99–100
 glucose. *See also* FDG-PET metabolism 53–4, 55, 56 transporters 53, 54
 GLUT glucose transporters 53, 54
 glycolysis 19–20
 grading
 brain tumors 75–6
 sarcomas 466, 467–8, 474–5
 granulosa-cell tumors 321
 ground states 1
 group numbers, databases 41
 guidelines
 ACCP 139
 EORTC 205
 lymphoma 330
 National Cancer Institute Trials 205
 Society of Nuclear Medicine 205
 half-life 1
 head and neck cancer/metastasis false positive PET/CT results 116–18
 FDG uptake 57, 58, 62–4, 65
 malignancy of unknown origin 448–9, 455–6
 metastases from unknown primary tumors 104–5
 nasopharynx cancer 112–14, 112–14
 recurrence detection 119–20, 119–20
 squamous cell carcinoma (HNSCC) 103, 109–11
 tonsillar carcinoma 106–8
 helical scans 13, 14
 hepatocellular carcinoma 245–6, 257, 264–5. *See also* liver cancer
 HER2 (human epidermal growth factor receptor 2) 269
 hexokinase 53–4
 histology. *See* classification; grading; tumor-nodal-metastasis classification
 HNSCC (head and neck squamous cell carcinoma) 103, 109–11
 Hodgkin's lymphoma 329–30, 344–6, 358–60, 362–4. *See also* lymphoma imaging patterns 331–2
 pediatric case studies 436–7
 hormone therapy 268–9
 Hounsfield units 14
 human epidermal growth factor receptor (HER2) 269
 human papillomavirus (HPV) 307
 Hürthle cell carcinoma 125–7
 hypoxia, PET probes 24–5
 image
 contrast 38–40
 fusion 48, 50–1
 registration 48–51
 relationship data 43
 resolution 35–6
 sampling 35
 image-presentation data module 44
 imatinib 206, 238
 immunotherapy 269
 implants, metallic 15–16, 204
 infectious paranasal sinus disease 116–18
 inflammatory cells 179
 information systems, PET 34, 51–2. *See also* three-dimensional imaging data processing 40 data transfer 41 databases 41 DICOM 41–3 image relationship data 43 stand-alone workstations/PACS 40–1 two-dimensional imaging 7–8, 34–40
 instance data modules 42
 Integrated International Workshop (IWG) response criteria, lymphoma 334
 integrins, PET probes 24
 International Harmonization Project 330, 338
 interventional procedures in diagnosis, PET/CT-guided 501. *See also* biopsy planning
 iteration 50
 iterative reconstruction, algorithms 10
 IUDs, physiological FDG uptake 295–301
 juvenile granulosa-cell tumors 321
 Ki-67 21
 Klein-Nishina formula 9
 large cell carcinoma 130
 LCIS (lobular carcinoma in situ) 267
 leiomyosarcoma, uterine 317–19
 lepidic growth 129
 linear attenuation coefficient 3, 14–15
 line-of-response (LOR) 3–4
 liver, FDG uptake 57, 58, 59, 64
 liver cancer/metastases 247
 biopsy planning 506–7, 508–9, 510
 cholangiocarcinoma 246–7, 256, 262–3
 hepatocellular carcinoma 245–6, 257, 264–5
 percutaneous tumor ablation 512–13, 514–15
 lobular carcinoma in situ (LCIS) 267
 look-up tables (LUT), color 37–8
 LOR (line-of-response) 3–4
 low grade Hodgkin's lymphoma (LGL) 330, 332
 lung, FDG uptake 57, 58, 62, 65
 lung cancer 128. *See also* non-small cell lung cancer; small cell lung cancer adenocarcinoma 161–4, 165–7 adenocarcinoma in situ 151–2, 153–4 diagnosis 135–9 differentiating from infection 156–7, 156–8 FDG-PET/CT 133, 135, 136–9, 142–3 imaging 12, 133 pleural mesothelioma 171–3 response to therapy, monitoring 141 squamous cell carcinoma 148–9, 168–9, 168–70 staging 130–1, 132, 133–4, 139–41 treatment overview 132, 134–5
 lung metastases biopsy planning 506–7 endometrial adenocarcinoma 312–14 leiomyosarcoma, uterine 317–19 malignancy of unknown origin 455–6 pediatric case studies 440–1
 lymph nodes. *See also* tumor-nodal-metastasis classification breast cancer 267, 268 esophageal cancer 177–8, 188 FDG uptake 56–8 Hodgkin's lymphoma 329–30, 331–2, 344–6 stomach cancer 205–6 supraclavicular 189–90
 lymphadenectomy, retroperitoneal 243
 lymphoma 329. *See also* chronic lymphocytic leukemia; classical Hodgkin's lymphoma; diffuse large B-cell lymphomas; Hodgkin's lymphoma classification using FDG PET-CT 329–31 FDG-PET-CT imaging patterns 331–4
 incurable 335
 large B-cell 82–3
 patient management 333–4
 pre-treatment evaluation 331
 prognosis 334
 recurrence, detecting 337–8
 response to therapy, monitoring 334–9
 semi-quantitative evaluation 338
 small lymphocytic (SLL) 351–3
 staging 331, 332–3
 timing of FDG-PET imaging 338
 magnetic resonance imaging. *See* MRI scanning
 malignancy of unknown origin, metastases 445–7
 breast cancer metastasis 452–3
 head and neck tumors 448–9, 450
 head and neck, breast, lung cancer 455–6
 neuroendocrine tumor 460–1
 pelvic cancer 463–5
 renal cell carcinoma 458–9
 thoracic/abdominal malignancy 450–1
 malignant meningioma 91, 93
 malignant mixed Mullerian tumors 315–16
 malignant pleural mesothelioma (MPM) 142–3, 171–3
 malignant transformation (MPNST) 468, 480
 mammography 267, 271
 mantle cell lymphoma (MCL) 330, 332. *See also* lymphoma
 mass number 1
 maximum acceptable ring difference 8
 maximum intensity projections (MIP) 47, 48
 maximum-likelihood image reconstruction 10
 measurement process, PET 3–4
 mediastinoscopy 134
 medication trials 493–4
 melanoma 366
 FDG-PET imaging 366
 FDG-PET/CT prognostic value 392–4
 follow-up 400–2, 400–5
 initial nodal staging 369–71
 initial distant staging 373–6
 PET/CT acquisition/processing parameters 367–8
 PET/CT versus PET and CT 387–90, 387–90
 response to therapy, monitoring 396–9
 satellite/in-transit metastases 378–84, 383–6
 staging 366, 367
 treatment overview 366

- meningioma, malignant 91, 92–3
menstruation, physiological FDG uptake 295–301
mercury levels 205
mesenchymal tissue tumors.
 See sarcomas
MET ([methyl-¹¹C] methionine 20
metabolism, glucose 53–4, 55, 56.
 See also FDG-PET
meta-data 44
metallic implants 15–16, 204
metastable states 2
metastases. *See also* malignancy
 of unknown origin
 adenocarcinoma 161–4, 313
 bone 409, **410**
 brain 76, 77, 84–6, 87, **88**, **89**
 breast 271
 classification. *See* tumor-nodal-
 metastasis classification
 colorectal **229**, 236–8
 endometrial 313
 esophageal 178, 187–8, 191–2
 head and neck 104–5, 106–8
 lung 133, 140–1, 159–60, 178
 melanoma 378–84, **383–6**
methionine, amino acid
 radiotracers 20, 79
methyl-¹¹C(choline) 23
MIP (maximum intensity
 projections) 47, **48**
mitosis, amino acid radiotracers
 79
monoclonal gammopathy of
 undetermined significance
 (MGUS) 419
movement artifacts 16–17
MPM (malignant pleural
 mesothelioma) 142–3, 171–3
MPNST (malignant
 transformation) 468, 480
MR cholangiopancreatography
 (MRCP) 243
MRI (magnetic resonance
 imaging) scanning
 brain tumors 76–7
 breast cancer **270**
 colorectal cancer 203
 esophageal cancer 176
 lung cancer 133
 malignant pleural
 mesothelioma 142
 pancreatic cancer 243
 sarcomas 467
multi-modality fused/
 synchronized imaging 50–1
multiple myeloma (MM) 418–19
mycobacterial infection, lung
 156–7, 156–8
nasopharynx cancer 112–14,
 112–14
National Cancer Institute Trials
 guidelines 205
National Comprehensive Cancer
 Network guidelines 330
National Electrical
 Manufacturers Association
 (NEMA) 42
neck cancer. *See* head and neck
 cancer
necrosis
 cell death 22
 lymphoma 338
 radiation injury 76
neuroblastoma 434–5
neuroendocrine tumor (NET)
 253, 255–7, 422–3
 from malignancy of unknown
 origin 446, 460–1
neurofibromatosis 480. *See also*
 sarcomas
nodes. *See* lymph nodes;
 tumor-nodal-metastasis
 classification
noise-equivalent count-rate
 (NECR) 10–11
non-colinearity, photons 4–5
non-Hodgkin's lymphoma 330,
 495, 497–8. *See also*
 lymphoma
non-rigid registration 50
non-small cell lung cancer
 (NSCLC) 128–30, **131**,
 159–60
 biopsy planning 508–9
 bone metastases 409, **410**
 response to therapy 491, **492**,
 499–500
 staging **132**
 treatment overview 135
normalization, PET information
 systems 40
object images 49
oblique views, three-dimensional
 imaging 46–7
occult primaries. *See* malignancy
 of unknown origin
oligodendroglioma 97, **98**, 99–100
osteosarcoma 406, 466, 473–5.
 See also sarcomas
 pediatric case studies 430–1
ovarian cancer 320–3
 metastatic tumor ablation
 514–15
 recurrence 325–7, **326–7**
ovary, FDG uptake 57, **58**, 67–9,
 295–301
oversimplification, PET
 interpretation 53
pacemakers 15–16
PACS (Picture Archiving and
 Communications System)
 40–1
Paget's disease 267
pancreatic cancer/metastases
 242, 247, **254**, 255
adenocarcinoma 250–2
 diagnosis 244
 FDG-PET/PET/CT 244
 malignancy of unknown origin
 460–1
 neuroendocrine 253, 255–7
 response to therapy,
 monitoring 245
 restaging 251, 253–4
 staging 242–3, 244–5
 treatment overview 243–4
paranasal sinus disease 116–18
paraneoplastic syndrome 452–3
partial-volume effects 18
parturition, physiological FDG
 uptake 295–301
patient
 data modules 42, **43**
 databases 41–3
 diet 19
 movement 16–17
PC (phosphocholine) 22
PCNSL (primary CNS
 lymphoma) 82–3
pediatric oncology 428
 astrocytoma, cerebellar 438–9
 Ewing's sarcoma 432–3
 neuroblastoma 434–5
 Hodgkin's lymphoma 436–7
 osteosarcoma 430–1
 thyroid cancer 440–1
 sarcomas 442–3, 466
pelvic cancer 463–5
pelvic extenteration 308
PEM (positron emission
 mammography) 271
percutaneous image-guided
 biopsies. *See* biopsy planning
percutaneous tumor ablation
 501, 512–13, 514–15
pessaries 295–301
PET probes. *See* probes, PET
PET-CT scanning. *See* FDG-
 PET/CT
PET-MRI, brain tumors 77
phosphatase 54
phosphocholine (PC) 22
photofraction 7
photons 1
 Compton-scattered 9
 non-colinearity 4–5
physiological FDG uptake
 53–4, 56–70
 bone 334, 407
 breast 269
 chemotherapy effects 70–2
 esophageal 179
 female reproductive tract 294,
 295, 297, 298, 299, 300, **301**
 head and neck 116–18
 infectious paranasal sinus 116–18
 lung 138, 156–7, 156–8
 lymphoma 334
 ovary 295–301
 pancreas 255
pessaries 295–301
post-surgical changes in
 uptake 70, 71
quantification of uptake 55–6
radiotherapy effects 72
thymus 57, 58, 62, 63, 334
pitch 13
pixels 35–6, 44
pleural mesothelioma, malignant
 (MPM) 142–3, 171–3
pleuropulmonary synovial
 sarcoma 485–6
point-spread function (PSF) 4
positrons 1
 annihilation 2–3
 decay 2
 emitters 2, 5
 range 4
positron emission
 mammography (PEM) 271
positronium 2
post-transplant
 lymphoproliferative
 disorder (PTLD) 334
primary CNS lymphoma
 (PCNSL) 82–3
probes, PET.1
 amino acid radiotracers 20–1
 androgen receptor 26–7
 angiogenesis 24
 cell proliferation/apoptosis
 21–2
 choline 22–3
 estrogen receptor 25–6
 fatty acid synthesis 27–8
 glycolysis 19–20
 hypoxia 24–5
 osseous tumors/metastases 25
 somatostatin receptor 27
proliferation, cell, PET probes
 21–2
prompt-coincidence windows 9
prostate cancer/metastases 26–7,
 425–6
prostate gland, FDG uptake 57,
 58, 69
PSF (point-spread function) 4
PTLD (post-transplant
 lymphoproliferative
 disorder) 334
pulse-height discriminators 7
radiation injury, and brain
 tumors 76
radioactive decay 1–2
radiofrequency (RF) ablation
 501, 512–13, 514–15
radiography 133, 467
radioimmunotherapy 335
radioisotopes 1
radionucleotides 1
radiotherapy 72
 breast cancer 268
 FDG uptake 56
 head and neck cancer 106–8

Index

- random coincidence events 8–10
 randoms-from-singles
 methodology 9
 reconstructed resolution 5
 rectal cancer 216–20, 219–24,
 226–31. *See also* colorectal
 cancer
 reference ranges, FDG uptake
 57, 58
 registered images 13
 renal cell carcinoma 458–9
 reproductive tract, female.
See female reproductive
 tract
 resolution, image 35–6
 resolution, spatial 4–6
 respiratory gating 137–8
 response to therapy, monitoring
 methodology 487
 breast cancer 271, 488–9
 clinical drug trial 493–4
 colorectal cancer 203,
 204–5, 215–17
 esophageal cancer 179, 198–9,
 490
 lung cancer 141, 491, 492,
 499–500
 non-Hodgkin's lymphoma
 495, 497–8
 pancreatic cancer 245
 sarcomas 469, 475
 stomach cancer 206
 retroperitoneal
 lymphadenectomy 243
 rhabdomyosarcoma 442–3, 466.
See also sarcomas
 rigid registration 50
 sagittal viewing modes 46
 salivary glands, FDG uptake 55,
 57, 58
 sampling, image 35
 sarcomas 466, 470–1, 474.
See also Ewing's sarcoma;
 GIST
 biopsy planning 468
 clinical management 466–7
 differential diagnosis/grading
 466, 467–8, 474–5
 FDG-PET 467–70, 474–5
 malignant transformation
 468, 480
 neurofibromatosis 480
 osteosarcoma 473–5
 other PET tracers 470
 prognosis 470
 recurrence, detecting 470, 475
 response to therapy,
 monitoring 469, 475
 staging with anatomic
 imaging 467
 synovial sarcoma 485–6
 TNM classification 468–9
 scatter coincidence events 8–10
 SCC. *See* squamous cell
 carcinoma
 scintillation crystals 6–7
 SCLC. *See* small cell lung cancer
 scrotum, FDG uptake 57, 58, 69
 series data modules 42
 Sestamibi 77–8, 85, 87
 sex cord stromal tumors 321
 sex hormone binding globulin
 (SHBG) 26
 sexually transmitted diseases,
 cervical cancer 307
 SGLT glucose transporters 53
 sigmoid colon cancer 226, 232–4
 single-event count-rates 9
 single photon emission computed
 tomography. *See* SPECT
 size, detector 4
 skeletal muscle, FDG uptake 55,
 57, 58, 66, 67, 68
 SLC2 (solute carrier family 2)
 53, 54
 SLC5A (solute carrier family 5A)
 53
 slice location 44
 slice thickness 44
 small cell lung cancer (SCLC) 129,
 130, 131, 132, 134, 141–2
 FDG-PET 141–2
 staging 132
 treatment overview 134
 small lymphocytic lymphoma
 (SLL) 351–3
 Society of Nuclear Medicine
 139, 205
 solitary pulmonary nodules
 (SPN) 135–9, 142–3, 148.
See also lung cancer
 somatostatin receptor 27, 422–3,
 461
 spatial resolution, PET images 4–6
 SPECT (single photon emission
 computed tomography)
 77–8, 85
 spill-out phenomena 18
 spinal cord, FDG uptake 56, 57,
 58, 60, 62
 spleen, FDG uptake 57, 58, 64
 squamous cell carcinoma
 (SCC) 128
 cervical cancer 306–9
 colorectal cancer 222, 226–31
 esophageal cancer 174
 lung cancer 142–3, 148–9,
 168–9, 168–70
 vulvar cancer 303–5, 306
 staging, tumor 293, 445. *See also*
 tumor-nodal-metastasis
 classification *and see specific*
cancers by name
 standalone PET scanners 12–13
 stand-alone workstations 40–1
 standardized uptake values.
See SUV
 stem cell transplantation 334–5
 step-and-shoot modes 13
 stomach cancer 205–6
 adenocarcinoma 233, 240
 diagnosis 205
 lymph node status 205–6
 recurrence, detecting 205
 response to therapy,
 monitoring 206
 stopping power 7
 study data modules 42
 subtraction techniques 9–10
 supraclavicular lymph nodes
 189–90
 surgery, post-surgical changes in
 FDG uptake 70, 71
 SUV-max (standardized uptake
 value) 17–18
 esophageal cancer 177, 182–4
 lymphoma 338
 pancreatic cancer 244
 sarcomas 467
 synchronized 3-D image
 triangulation 50–1
 synovial sarcomas 466, 485–6.
See also sarcomas
 system resolution 5
 systemic staging, breast cancer
 271. *See also* metastases
 target images 49
 Tc-labeled Annexin-V 22
 testis, FDG uptake 57, 58, 69
 thallium 77, 87
 thecomas 321
 thoracentesis 134
 thoracoscopy 134
 thoracotomy 134
 three-dimensional imaging 43,
 44, 51–2
 acquisition modes 7–8
 creating 3-D matrix 44, 45
 DICOM 47–8
 image registration/fusion
 48–51
 maximum intensity
 projections 47, 48
 multi-modality fused/
 synchronized imaging 50–1
 oblique views 46–7
 triangulation viewing modes
 46, 47
 thymidine 22
 thymidine kinase 21–2
 thymus, FDG uptake 57, 58,
 62, 63, 334
 thyroid cancer 103, 122–3,
 125–7, 413–14
 pediatric case studies 440–1
 thyroid gland, FDG uptake 57,
 58, 62
 thyroid transcription factor
 (TTF1) 445
 time-of-flight 7
 tongue, FDG uptake 57,
 58, 62, 63
 tonsillar carcinoma 106–8
 transition energy 1
 transmission scans 12
 transporters, glucose 53, 54
 trans-thoracic needle aspiration
 (TTNA) 133
 triangulation viewing modes
 46, 47
 Troisier's sign 189–90
 true coincidence events 8–10
 tyrosine 21
 tumor ablation 501, 512–13,
 514–15
 tumor-nodal-metastasis (TNM)
 classification. *See also*
 staging *and specific cancers*
by name
 esophageal cancer 175,
 177–8
 lung cancer 130–1, 132,
 139–41, 178
 melanoma 366, 367,
 369–71, 373–6
 pancreatic cancer 242–3
 sarcomas 468–9
 two-dimensional imaging 7–8,
 34–40
 typical carcinoids 130
 ultrasound, endoscopic 176
 unstable nuclei 1
 uremia 307, 308
 urinary tract, FDG uptake 57,
 58, 66
 uterus
 carcinosarcoma 315–16
 FDG uptake 57, 58, 67–9
 fibroids 295–301
 leiomyosarcoma 317–19
 Virchow's lymph node
 189–90
 vocal cords, FDG uptake 57, 58,
 62, 63
 voxels 44
 vulvar cancer 303–5, 306
 websites, DICOM 42
 Whipple
 pancreaticoduodenectomy
 243
 window-leveling 38–40
 World Health Organization
 classification, meningioma 93